^
Association details:
| Biomarker: | AR positive |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase II trial of bicalutamide in combination with palbociclib for the treatment of androgen receptor (+) metastatic breast cancer.
Published date:
05/13/2020
Excerpt:
In this selected subset of pts with AR+ TN MBC, this study met its prespecified endpoint with 11 pts PF at 6 mo on B 150 mg + P 125 mg. B+P has been well tolerated with no unexpected toxicity observed.
Secondary therapy:
bicalutamide
DOI:
10.1200/JCO.2020.38.15_suppl.1017
Trial ID:
